Summary & Overview
HCPCS C9743: Injection/Implantation of Bulking or Spacer Material
HCPCS Level II code C9743 denotes the injection or implantation of bulking or spacer material (any type), with or without image guidance, and is intended for use when no more specific code applies. Nationally, this code captures a variety of minimally invasive procedures across specialties where tissue augmentation or creation of a spacer is required — procedures that can affect device utilization, imaging resources, and procedural coding consistency.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of coding scope and clinical context, common sites of service, and areas where payer policy and code specificity commonly intersect. The publication provides benchmarks for utilization patterns and reimbursement themes, highlights policy updates that influence coding choice, and summarizes implications for documentation and claims adjudication.
The content is intended for a national audience of billing professionals, revenue cycle managers, and clinicians who need concise guidance on when C9743 may apply, what procedural settings it covers, and where to expect variability in payer coverage or requirement for more specific codes. Data not available in the input is noted explicitly in relevant sections.
Billing Code Overview
HCPCS Level II code C9743 describes the injection or implantation of bulking or spacer material (any type) and may be performed with or without image guidance. The procedure can be used to add tissue bulk or create space in a targeted anatomical area when clinically indicated. The description indicates it is intended as a general code to be used when a more specific code does not apply.
Service type: Injection or implantation of bulking/spacer material
Typical site of service: Ambulatory surgical centers, hospital outpatient departments, physician offices, or other procedural settings where image guidance is available
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with urinary incontinence or pelvic floor dysfunction who has failed conservative management (pelvic floor therapy, medications) and is scheduled for endoscopic injection of periurethral bulking or implantation of spacer material. The patient arrives to an outpatient ambulatory surgery center or hospital-based endoscopy suite. Preprocedure evaluation includes focused history, informed consent, assessment for anticoagulation, and a targeted genitourinary exam. Local or regional anesthesia with IV sedation is commonly used; general anesthesia may be used based on patient comorbidity or concurrent procedures. The procedure is performed cystoscopically with direct visualization; sterile technique and image guidance (cystoscopic or fluoroscopic) are available as needed. A bulking agent or spacer material is injected into the periurethral or peri-vesical tissue to improve urethral coaptation and reduce stress urinary leakage. Postprocedure, the patient is monitored for immediate complications (hematuria, urinary retention, infection), instructed on voiding trials, activity restrictions, and follow-up urology or urogynecology clinic visit for outcome assessment and need for repeat injections.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day | Use when a distinct E/M visit is performed on the same day as the injection/implantation |